What is the recommended dosing for nifedipine (including immediate‑release and extended‑release formulations)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 8, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Nifedipine Dosing Recommendations

For nifedipine extended-release formulations, start with 30 mg once daily and titrate up to 60 mg once daily as the usual maintenance dose, with a maximum of 90 mg daily; for immediate-release nifedipine, the dose is 30-90 mg daily in divided doses, but this formulation should be avoided in acute coronary syndromes unless the patient is on concurrent beta-blocker therapy. 1, 2, 3

Extended-Release Formulations (Preferred)

Standard Dosing Algorithm

  • Initial dose: 30 mg once daily on an empty stomach 3
  • Titration: Increase over 7-14 days based on blood pressure response and tolerability 3
  • Usual maintenance: 30-60 mg once daily 1, 2, 3
  • Maximum dose: 90 mg once daily (titration above 90 mg is not recommended) 1, 2, 3

Critical administration detail: Extended-release tablets must be swallowed whole—never crushed, chewed, or divided 3. This is essential to maintain the controlled-release mechanism.

Bioequivalence Considerations

When prescribing 90 mg daily, use a single 90 mg tablet rather than three 30 mg tablets. Three 30 mg tablets produce substantially higher peak concentrations (Cmax 29% greater) than a single 90 mg tablet, increasing the risk of adverse effects like hypotension and reflex tachycardia 3. However, two 30 mg tablets are interchangeable with one 60 mg tablet 3.

Immediate-Release Formulations

Dosing: 30-90 mg daily in divided doses 1, 2

Critical Safety Warning

Immediate-release nifedipine must be avoided in acute coronary syndromes (unstable angina/NSTEMI) unless the patient is on concurrent beta-blocker therapy 4, 5. This is a Class III (Harm) recommendation based on evidence showing increased mortality and adverse cardiovascular events when used alone in ACS patients 1. The Holland Interuniversity Nifedipine/metoprolol Trial was stopped early due to harm with nifedipine monotherapy, though patients already on beta-blockers appeared to benefit (risk ratio 0.68) 1.

Special Populations

Pregnancy and Hypertensive Disorders

For hypertension in pregnancy, extended-release nifedipine is a first-line agent 6. Dosing options include:

  • 30 mg twice daily (BID)
  • 60 mg once daily (QD)

Recent evidence shows no difference in blood pressure control between these regimens 7, making once-daily dosing preferable for patient convenience and compliance. For acute hypertensive crises in pregnancy, 10 mg sublingual immediate-release nifedipine may be used 8.

Pediatric Dosing

For hypertensive crises in children 9:

  • <10 kg: 2.5 mg sublingual
  • 10-20 kg: 5 mg sublingual
  • >20 kg: 10 mg sublingual

Extract capsule contents and give directly for more rapid effect in younger children.

Elderly Patients

Elderly patients (>60 years) show 36% higher peak concentrations and 70% greater average plasma levels compared to younger patients 3. Despite this, no specific dose reduction is mandated, but start at the lower end of the dosing range and monitor closely for hypotension and edema.

Hepatic Impairment

Patients with liver cirrhosis have longer elimination half-life and higher bioavailability 3. Use caution and consider starting with lower doses, though specific dose adjustments are not established.

Common Pitfalls and Caveats

Food Effects

Avoid grapefruit juice entirely—it increases nifedipine AUC and Cmax up to 2-fold through CYP3A4 inhibition 3. High-fat meals increase peak concentration by 60% and prolong time to peak 3. For consistency, administer extended-release formulations on an empty stomach 3.

Drug Interactions

Nifedipine is metabolized via CYP3A4 3. Strong CYP3A4 inhibitors (e.g., azole antifungals, macrolides, protease inhibitors) will increase nifedipine levels, while inducers (e.g., rifampin, phenytoin) will decrease levels. Adjust dosing accordingly and monitor blood pressure closely.

Contraindications in Cardiac Conditions

Avoid nifedipine in:

  • Pulmonary edema 1
  • Severe left ventricular dysfunction 1
  • Acute coronary syndromes without beta-blocker coverage 4, 5

For patients with ongoing ischemia who cannot tolerate beta-blockers, use non-dihydropyridine calcium channel blockers (diltiazem or verapamil) instead 4, 5.

Side Effects

Most common adverse effects include hypotension, dizziness, flushing, nausea, constipation, and peripheral edema 1, 2. In critically ill patients, 27% experienced clinically significant hypotension (≥15% SBP reduction) within 1 hour of immediate-release nifedipine administration 10.

Discontinuation

If discontinuation is necessary, taper the dose gradually under close supervision rather than stopping abruptly 3.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.